Compare FMC Corp (FMC) vs Tempus AI (TEM) Price & Performance

FMC Corporation (FMC) trades at $10.72, down 1.74% on the day, reflecting ongoing challenges despite recent strategic moves. The stock shows a bearish technical trend with oversold RSI signals, while fundamentals reveal significant pressure with a net income margin of -72.93% and negative ROE of -80.78% for 2025. Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submission for new herbicide rimisoxafen, providing some operational support amid financial restructuring.

The outlook remains cautious with analyst consensus leaning neutral (50% Hold) despite a $16 price target suggesting 49% upside. Key risks include persistent revenue declines, high debt levels, and negative cash flow from operations. Investment opportunity exists if new product approvals and debt reduction efforts successfully stabilize profitability, but current financial metrics indicate substantial execution risk near term.

Tempus AI (TEM) trades at $55.62, down 5.1% over 24 hours, with a neutral technical signal and bullish moving average alignment. The company reported Q1 2026 revenue growth and an earnings beat, though it remains unprofitable with a net margin of -22.2%. Recent news highlights FDA clearances and partnerships, while analyst consensus is strongly positive with a $68.50 price target.

The outlook balances high-growth potential in AI-driven healthcare data against significant near-term losses. Investment opportunity lies in Tempus's unique data platform and expanding market reach, but risks include persistent cash burn and competitive pressures. Upside depends on achieving profitability and scaling high-margin segments.